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Background. Women in Africa, especially young women, have very high human immunodeficiency virus (HIV)
incidence rates that cannot be fully explained by behavioral risks. We investigated whether genital inflammation in-
fluenced HIV acquisition in this group.
Methods. Twelve selected cytokines, including 9 inflammatory cytokines and chemokines (interleukin
[IL]-1α, IL-1β, IL-6, tumor necrosis factor-α, IL-8, interferon-γ inducible protein-10 [IP-10], monocyte chemoat-
tractant protein-1, macrophage inflammatory protein [MIP]-1α, MIP-1β), hematopoietic IL-7, and granulocyte
macrophage colony-stimulating factor, and regulatory IL-10 were measured prior to HIV infection in cervicovaginal
lavages from 58 HIV seroconverters and 58 matched uninfected controls and in plasma from a subset of 107 of these
women from the Centre for the AIDS Programme of Research in South Africa 004 tenofovir gel trial.
Results. HIV seroconversion was associated with raised genital inflammatory cytokines (including chemokines
MIP-1α, MIP-1β, and IP-10). The risk of HIV acquisition was significantly higher in women with evidence of genital
inflammation, defined by at least 5 of 9 inflammatory cytokines being raised (odds ratio, 3.2; 95% confidence interval,
1.3–7.9; P = .014). Genital cytokine concentrations were persistently raised (for about 1 year before infection), with
no readily identifiable cause despite extensive investigation of several potential factors, including sexually transmitted
infections and systemic cytokines.
Conclusions. Elevated genital concentrations of HIV target cell–recruiting chemokines and a genital inflamma-
tory profile contributes to the high risk of HIV acquisition in these African women.
Keywords. HIV transmission; female genital tract; inflammation; cytokine.
Substantial progress has been made in slowing the glob-
al human immunodeficiency virus (HIV) epidemic over
the past decade, with the annual number of new HIV
infections declining from 3.4 million in 2001 to 2.1 mil-
lion in 2013 [1]. Despite this achievement, the HIV
epidemic continues to grow among young women in
Africa, with HIV infection rates up to 8-fold higher
than in men of the same age [2]. In South Africa, na-
tional HIV prevalence rates among pregnant women
have risen from 24.8% in 2001 to 29.5% in 2012 [3].
These high HIV prevalence rates are being sustained
by incidence rates as high as 9.1/100 person-years in
women from KwaZulu-Natal in South Africa [4]. Re-
ported incidence rates are particularly concerning in
teenaged girls who have HIV incidence rates of up to
17.2/100 person-years [5]. Continual transmission of
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HIV infection in young women in southern Africa is one of the
greatest challenges preventing the world from achieving the goal
of an AIDS-free generation [6].
Multiple partners, sexual frequency, low condom use rates,
sexual violence [7], and sexually transmitted infections (STIs)
[8, 9] have been shown to have an impact on the risk of young
African women acquiring HIV. While there is a growing under-
standing of factors that impact HIV acquisition, these factors,
singly or in combination, are insufficient to fully explain the
heightened vulnerability of young women in southern Africa.
Inflammatory cytokines such as macrophage inflammatory
protein (MIP)-1α, MIP-1β, and interleukin (IL)-8 in the genital
tracts of rhesus macaques were found to be essential for estab-
lishment of a productive simian immunodeficiency virus (SIV)
infection following vaginal exposure [10], and STIs that cause
inflammation are associated with increased susceptibility to
HIV infection [11]. For these reasons, we hypothesized that an
inflammatory milieu in the human female genital tract increases
the risk of HIV acquisition. In macaques, these chemokines led
to the recruitment of CD4+ T-cell targets at the early stages
of infection, thereby facilitating SIV replication. Furthermore,
topical application of the antiinflammatory agent, glycerol-
monolaurate, downregulated inflammatory chemokine concen-
trations, inhibited inflammatory cell influx to the genital tract,
and thereby prevented SIV infection in macaques [10].
The purpose of this study was to assess whether genital in-
flammation was associated with an increase in the risk of HIV
acquisition in South African women.
METHODS
Study Design
A total of 889 HIV-uninfected women were enrolled in the
Centre for the AIDS Programme of Research in South Africa
(CAPRISA) 004 phase IIb, double-blind, tenofovir gel trial in
rural Vulindlela and urban eThekwini in KwaZulu-Natal,
South Africa [4]. Women were randomized to use either hy-
droxyethylcellulose placebo or tenofovir gel. Women were en-
rolled and followed between May 2007 and March 2010.
HIV testing was conducted monthly using 2 rapid HIV anti-
body tests (Abbott Determine and Unigold) and confirmed with
2 independent RNA-polymerase chain reaction (PCR) assays at
least 1 week apart. Stored plasma samples from prior visits by
each seroconverter were tested using PCR to identify the window
period of HIV infection (RNA-PCR–positive but rapid HIV
test–negative). Quarterly pelvic examinations were performed,
cervicovaginal lavages (CVLs) were collected (Supplementary
Material), and the presence of genital abnormalities was recorded.
Serology was performed for herpes simplex virus type 2 (HSV-2)
using the HSV-2 gG2 enzyme-linked immunosorbent assay
(Kalon Biologicals Ltd.). Chlamydia trachomatis, Neisseria
gonorrhoeae, Treponema pallidum, Trichomonas vaginalis,
Haemophilus ducreyi, and HSV-1 and -2 were assessed using
real-time PCR (Supplementary Material).
Fifty-eight HIV seroconverters who had preinfection CVLs in
storage that did not have visible blood contamination were includ-
ed. Of the available samples for each participant, those who were
closest to the estimated time of HIV infection were analyzed (me-
dian 4.5 months prior to HIV infection; interquartile range [IQR],
2.4–6.9 months). Each of the 58 cases had a negative PCR test re-
sult on the same day as the sample used for analysis or at a visit
after sample collection. The 58 cases included 23 women assigned
to the tenofovir gel arm of the study. HIV negative controls
(n = 58) were matched on gel assignment and date of CVL collec-
tion (each had a CVL available within 7 days of the date of sample
collection for each case) in order to minimize the possible effects of
product use and sample storage time on cytokine concentrations.
The University of KwaZulu-Natal’s and University of Cape
Town’s research ethics committees approved this study, and
all participants provided written informed consent.
Measurement of Cytokine Concentrations
Luminex was used to measure the concentrations of 12 cytokines
(IL-1α, IL-1β, IL-6, IL-7, IL-8, IL-10, granulocyte macrophage col-
ony-stimulating factor [GM-CSF], interferon-γ inducible protein
[IP]-10, monocyte chemoattractant protein [MCP]-1, MIP-1α,
MIP-1β, and tumor necrosis factor [TNF]-α) in preinfection
CVLs from women who later became HIV-infected (median 4.5
months preinfection [IQR, 2.4–6.9 months]), and in CVLs from
women who remained HIV-uninfected during the follow-up peri-
od [4] (Supplementary Material). The 12 cytokines were selected
based on their previously identified association with genital infec-
tions and/orHIV disease progression [11–13]and the fact that they
could be reproducibly measured in CVL (Supplementary Table 1).
To determine whether the raised cytokine profiles found in
women prior to HIV infection were acute or persistent, 57 CVL
samples (21 women who later acquired HIV infection and 36
women who remained uninfected) were available from a second
time point at a median of 48 weeks from the first time period
(range, 8–104 weeks). Cytokine concentrations were also mea-
sured in matching plasma samples from a subset of 107 women
(57 cases and 50 controls) for whom plasma was available.
Statistical Analyses
Unsupervised hierarchical clustering was used to group women
according to the relatedness of their cytokine expression profiles.
Conditional logistic regression was used for the matched-pair
case-control analysis. P values were adjusted for multiple com-
parisons using a false discovery rate step-down procedure
[14]. Partial least squares discriminant analysis (PLSDA) [15]
was used to determine multivariate cytokine profiles that best dis-
tinguished between cases and controls (Supplementary Material).
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RESULTS
Genital Cytokine Concentrations and HIV Acquisition
Womenwho acquiredHIV infection (n = 58) during the CAPRISA
tenofovir gel trial had higher genital concentrations of the chemo-
tactic cytokinesMIP-1α, MIP-1β, IL-8, and IP-10 prior to infection
(Table 1) than matched women who remained HIV-negative
(n = 58). The women who acquired HIV infection also clustered
separately from women who remained uninfected in an unsuper-
vised hierarchical analysis of the 12 cytokines (Figure 1).
Genital Inflammatory Profiles and HIV Acquisition
Of the 12 cytokines measured in this study, 9 are classified
as proinflammatory or chemotactic (MIP-1α, MIP-1β, IP-10,
Table 1. Relationship Between Genital Tract Cytokines and Risk of Human Immunodeficiency Virus Infection in Women From the Centre









Value% Detectable (n) % Detectable (n) Per Detection of Cytokine
MIP-1β 43.1 (25) 75.9 (44) 3.17 (1.49–6.77) .003a
MIP-1α 15.5 (9) 44.8 (26) 3.09 (1.38–6.92) .006a
GM-CSF 75.9 (44) 89.7 (52) 2.64 (.87–8.05) .086
IL-7 58.6 (34) 60.3 (35) 1.06 (.52–2.15) .874
Median (IQR) log10 pg/mL Median (IQR) log10 pg/mL Per 1 log10 pg/mL increase
IP-10 1.88 (0.94–2.47) 2.26 (1.54–2.86) 1.94 (1.19–3.17) .008a
IL-8 2.81 (2.41–3.28) 3.18 (2.82–3.92) 1.85 (1.09–3.13) .022
IL-1α 1.97 (1.61–2.44) 2.22 (1.71–2.74) 1.65 (.96–2.83) .067
MCP-1 1.31 (0.82–1.68) 1.43 (0.94–1.89) 1.47 (.85–2.54) .164
IL-10 −0.37 (−1.70–0.33) −0.14 (−0.89–0.55) 1.21 (.91–1.60) .197
IL-6 0.79 (0.25–1.29) 0.87 (0.50–1.41) 1.23 (.75–2.01) .419
IL-1β 0.27 (−0.42–1.02) 0.52 (−0.32–1.27) 1.22 (.86–1.73) .265
TNF-α −0.68 (−1.10–0.01) −0.62 (−1.05–0.31) 1.16 (.76–1.77) .498
Abbreviations: GM-CSF, granulocyte macrophage colony-stimulating factor; HIV, human immunodeficiency virus; IL, interleukin; IP-10, interferon-γ inducible protein-
10; IQR, interquartile range; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; TNF-α, tumor necrosis factor-alpha.
a Statistically significant after adjusting for multiple comparisons.
Figure 1. Unsupervised hierarchical clustering was used to visualize the variation in cytokine concentrations in individual women and to cluster women
according to the similarities of their cytokine expression profiles (using Qlucore Omics Explorer). Women who later became human immunodeficiency virus
(HIV)–infected (n = 58; blue blocks) had upregulated preinfection cervicovaginal lavage cytokine concentrations and tended to cluster together, while women
who remained HIV-uninfected had lower cytokine concentrations and also clustered together (n = 58; yellow blocks). Cytokine concentrations are indicated
using a color scale that ranges from green (low) through black to red (high). The dendrogram above the heat map illustrates degrees of relatedness between
genital cytokine profiles evident within the various women. The dendrogram on the left-hand side of the heat map indicates relationships between the
expression profiles of the analyzed cytokines across all of the women assessed in this study. Abbreviations: GM-CSF, granulocyte macrophage colony-
stimulating factor; IL, interleukin; IP-10, interferon-γ inducible protein-10; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory pro-
tein; TNF-a, tumor necrosis factor-alpha.
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IL-8, MCP-1, IL-1α, IL-1β, IL-6, and TNF-α), while IL-10 is
antiinflammatory and GM-CSF and IL-7 are hematopoietic
[16–22]. The risk of HIV acquisition was significantly higher
in women who had elevated genital inflammatory cytokines
(odds ratio [OR], 3.2; 95% confidence interval [CI], 1.3–7.9;
P = .014), as indicated by raised levels of at least 5 of the 9 proin-
flammatory or chemotactic cytokines assessed (Table 2).
The women who later became HIV-infected and those who
remained negative had similar demographic characteristics
(Table 3).Women who became infected had a slightly higherme-
dian number of monthly sex acts and returned used gel applica-
tors (Table 3). The increased risk of HIV acquisition associated
with genital inflammation was evident in women assigned to
both tenofovir and placebo gel and did not change after adjusting
for age, urban/rural residence, condom use, hormonal contracep-
tives, number of sex acts, number of returned used applicators,
and HSV-2 serostatus (OR, 3.8; 95% CI, 1.3–11.2; P = .016).
Irrespective of the definition of genital inflammation applied,
using various permutations of the 12 cytokines, the relationship
between cytokine profiles and HIV infection risk remained ev-
ident. Women with ≥4 (OR, 2.4; 95% CI, 1.1–5.3) or ≥6 (OR,
3.0; 95% CI, 1.0–9.3) of these 9 cytokines above the 75th percen-
tile were at increased risk of HIV infection. Furthermore,
women with ≥3 (OR, 3.2; 95% CI, 1.3–7.9) or ≥4 (OR, 10.0;
95% CI, 1.3–78.1) of the 5 chemokines assessed (MIP-1α,
MIP-1β, IP-10, IL-8, and MCP-1) above the 75th percentile
were at increased risk of HIV acquisition.
PLSDA has previously been used to identify multivariate
combinations of features that best differentiate individuals
based on disease status [15]. Using this approach, we identified
specific cytokine profiles that differentiated women who ac-
quired HIV infection from those who remained uninfected.
Latent variable 1 (LV1) of our PLSDA model best separated women who became infected from those who remained unin-
fected (Figure 2A). Women who later became infected had
higher levels of cytokines positively loaded on LV1 (MIP-1α,
MIP-1β, IP-10, IL-8, IL-1α, IL-1β, IL-6, TNF-α, IL-7, and IL-
10) and comparatively lower levels of cytokines negatively load-
ed on LV1 (MCP-1 and GM-CSF; Figure 2B). A conditional
logistic regression using the LV1 scores as an independent var-
iable determined that the odds of HIV acquisition were 2.9-fold
(95% CI, 1.5–5.3; P = .0009) higher in women with this cytokine
profile. Furthermore, using this PLSDA model, MIP-1α, MIP-
1β, IP-10, and IL-8 were identified as the most critical of the
12 cytokines for classifying the 2 groups (evidenced by variable
importance projection [VIP] scores >1). This result using a rel-
atively unbiased approach was in agreement with our univariate
analysis of cytokines (Table 1).
Persistence of Raised Genital Inflammatory Cytokines
The raised genital inflammatory cytokine levels were not short-
lived (Figure 3). In a longitudinal analysis, genital cytokine
Table 2. Association Between Genital Inflammation Prior to
Human Immunodeficiency Virus (HIV) Infection and HIV
Acquisition in Women From the Centre for the AIDS Programme




Genital inflammation present 19 6
Genital inflammation absent 39 52
Total 58 58
Pair-matched odds ratio (95% confidence interval) 3.2 (1.3–7.9)
P value .014
Abbreviation: HIV, human immunodeficiency virus.
a Women who had at least 5 of the 9 inflammatory cytokines (interleukin [IL]-
1α, IL-1β, tumor necrosis factor-alpha, IL-6, IL-8, interferon-γ inducible protein-
10, monocyte chemoattractant protein-1, macrophage inflammatory protein
[MIP]-1α, MIP-1β) above the 75th percentile concentration for each cytokine
were categorized as having genital inflammation.
Table 3. Demographic, Behavioral, and Clinical Characteristics
of the Women Who Acquired Human Immunodeficiency Virus









Median (IQR) Median (IQR)
Age, in years 22 (20–24) 22 (20–26)
Number of sexual partners in
lifetime
2 (1–3) 2 (1–3)
Returned used applicators per
month
7 (6–10) 6 (4–8)a
Reported sexual intercourse
per month
5 (3–8) 4 (3–6)a
% (n) % (n)
Reside in rural setting 65.5 (38) 70.7 (41)
Completed high school 43.1 (25) 39.7 (23)
Gave birth previously 75.9 (44) 81.0 (47)
Married 1.7 (1) 8.6 (5)
Stable partner 94.8 (55) 89.7 (52)
Reported always using a
condom during sex
34.5 (20) 27.6 (16)
Baseline contraception
Injectable 91.4 (52) 82.8 (48)
Oral contraceptive pill 8.6 (5) 13.8 (8)
Tubal ligation/hysterectomy 0.0 (0) 3.5 (2)
Baseline genital discharge 32.8 (19) 20.7 (12)
Herpes simplex virus type-2
prevalence
64.9 (37/57b) 51.7 (30)
Assigned to use tenofovir gel 39.7 (23) 39.7 (23)
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range.
a P < .05 on a Wilcoxon signed rank test for paired data.
b One woman had no sample to test.
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concentrations at 2 time points were examined in 21 women
who later acquired HIV and in 36 women who remained unin-
fected (median time between sampling was 48 weeks [range, 8–
104]). The correlation coefficient for the cytokine concentra-
tions at these 2 time points was >0.3 for IL-1α, IL-1β, IL-6,
TNF-α, MIP-1β, IL-7, and MCP-1 (P < .05 following adjust-
ment for multiple comparisons; Figure 3), indicating that
women with the highest cytokine concentrations at one time
point ranked similarly at the second time point. In a
matched-pair analysis (Supplementary Table 2), the concentra-
tions of 11 of 12 cytokines did not differ significantly between
the 2 time points.
Searching for Possible Causes of Raised Genital Inflammatory
Cytokines
No significant associations were found between having a raised
genital inflammatory profile (defined by ≥5 of 9 inflammatory
cytokines above the 75th percentile) and vaginal discharge,
genital ulceration, HSV-2 serostatus, contraceptive choice, in-
travaginal substance use, presence of a stable partner, parity,
and reported sex acts per month (Table 4). Women without
genital inflammation reported less frequent condom use
(P = .05). None of the inflammatory cytokines measured in
CVLs differed between women in the tenofovir and placebo
arms (Figure 4).
Associations between genital and plasma cytokine concentra-
tions were investigated in a subset of women (n = 107). Plasma
cytokine concentrations were not elevated in women who had
raised genital cytokines (n = 23) compared with women who
did not have raised genital cytokine concentrations (n = 84;
Table 4). Further, plasma and genital cytokine concentrations
did not correlate significantly (data not shown).
Samples for STI testing were available for 20 of 25 women
with raised genital inflammatory profiles and 68 of 91 without
evidence of genital inflammation. Ten women with genital in-
flammation (50.0%) and 23 women without genital inflamma-
tion (33.8%) were PCR positive for T. vaginalis, C. trachomatis,
N. gonorrhoeae, or HSV-2 (P = .20; Table 4). Twenty percent of
the raised genital inflammatory cytokines measured in this
study could be attributed to the presence of any one of the com-
mon STIs caused by these organisms. The strongest association
with genital inflammation was with T. vaginalis. These results
show that STIs (including those caused by T. vaginalis) could
not fully explain the majority of genital inflammation that
was detected in this study, suggesting that other inflammatory
mediators may play a role.
Elevated IL-6, IP-10, MCP-1, and MIP-1β concentrations
were significantly associated with younger age, after adjusting
for discharge, STIs, and hormone contraceptive use (β-coefficient
per 5 year decrease in age [P value]: 0.31 log10 pg/mL [P = .002],
0.43 log10 pg/mL [P = .001], 0.63 log10 pg/mL [P = .002], and
0.32 log10 pg/mL [P = .041], respectively). Age, however, did
not differ among women defined as having genital inflammation
compared with those who did not (Table 4).
Figure 2. Identification of multivariate cytokine profiles associated with human immunodeficiency virus (HIV) infection at a later time. A, Partial least
squares discriminant analysis model of all 12 cytokines classified individuals with 65% overall accuracy for classification and 63% accuracy for cross-
validation (blue, remain uninfected; red, become infected). B, Latent variable 1 best separated individuals who became infected with HIV from those
who remained uninfected. Cytokine loadings indicate multivariate cytokines associated with HIV infection. Since individuals who became infected with
HIV clustered in the positive region of latent variable 1 (LV1) (A), cytokines positively loaded on LV1 (macrophage inflammatory protein [MIP]-1α, MIP-1β,
interferon-γ inducible protein-10 [IP-10], interleukin [IL]-8, IL-1α, IL-1β, IL-6, tumor necrosis factor-alpha [TNF-α], IL-7, and IL-10) (B) are elevated in profiles
of those who became infected while negative loadings (monocyte chemoattractant protein-1 [MCP-1], granulocyte macrophage colony-stimulating factor
[GM-CSF]) were comparatively reduced. Logistic regression analysis indicated that higher scores on LV1 were associated with a 2.86-fold (95% confidence
interval, 1.54–5.30 and P = .0009) higher odds of infection. Variable importance projection scores indicated that MIP-1α, MIP-1β, IL-8, and IP-10 were most
important for classification of the 2 groups.
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DISCUSSION
Raised genital tract inflammatory cytokine concentrations were
found to be an important risk factor for HIV acquisition in the
women in this study. Women with a genital inflammatory pro-
file (≥5 of 9 inflammatory cytokines elevated) were at signifi-
cantly increased risk of HIV acquisition (OR, 3.2; 95% CI,
1.3–7.9). The raised cytokine concentrations were sustained
for 1 year, on average, prior to infection, suggesting the presence
of persistent genital inflammatory signatures.
Higher concentrations of chemotactic cytokines IP-10, MIP-
1α, MIP-1β, and IL-8 were each associated with increased HIV
acquisition risk and were identified as the most influential me-
diators to differentiate women who subsequently became HIV
infected from those who remained HIV negative using PLSDA
and VIP analyses. IP-10, MIP-1α, and MIP-1β are chemotactic
for potential HIV target cells, including T cells, monocytes,
macrophages, and dendritic cells [10, 23–25]. MIP-1α and
MIP-1β, in particular, bind to the HIV coreceptor C-C chemo-
kine receptor type 5 (CCR5) and specifically recruit CCR5+ tar-
get cells that potentially enhance HIV infection [26]. Although
previous studies in exposed seronegative women and in vitro
models suggested that MIP-1α and MIP-1βmay protect against
HIV infection by competitively inhibiting HIV binding to
CCR5 [27, 28], it has been suggested that exposed seronegative
women have higher genital concentrations of these chemokines
compared with HIV-uninfected low-risk women because they
are more likely to have STIs [29]. Furthermore, although
MIP-1α and MIP-1β may competitively inhibit HIV in vitro,
these models do not account for the fact that the production
of these chemokines may be accompanied by upregulation
of other inflammatory factors or recruitment of HIV target
cells that may facilitate HIV replication in vivo. In macaques,
production of these and other inflammatory cytokines was
found to be essential for recruitment of CD4+ T cells needed
for SIV replication [10]. IL-8, which similarly correlated with
susceptibility to HIV infection in this study, has also been asso-
ciated with increased HIV transmission in cervical explant tis-
sue [30].
There was little correlation between elevation of cytokines in
the genital tract and plasma. This is in keeping with other re-
ports that genital cytokine concentrations are not related to sys-
temic cytokine concentrations [31, 32]. Combined, the evidence
points to a genital compartment factor as a likely cause of the
persistent genital inflammation that predisposed these women
to HIV acquisition.
Figure 3. Spearman correlations between genital tract cytokine concentrations in the same women (n = 57) at 2 time points (median 48 weeks apart
[range, 8–104]). The correlation coefficient was >0.3 (P < .05) for interleukin (IL)-1α, IL-1β, IL-6, tumor necrosis factor-alpha (TNF-α), monocyte chemoat-
tractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1β, and IL-7, and these associations remained significant following adjustment for
multiple comparisons. Abbreviations: GM-CSF, granulocyte macrophage colony-stimulating factor; IP-10, interferon-γ inducible protein-10.
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Table 4. Relationship Between Genital Inflammation and Possible Behavioral, Clinical, and Systemic Causes
Demographic and Behavioral Characteristic
Genital Inflammation
Present (n = 25)
Genital Inflammation
Absent (n = 91)
P Value% (n) % (n)
Age in years (median [IQR]) 22 (20–24) 22 (20–25) .40
Assigned to use tenofovir gel 36.0 (9) 40.7 (37) .82
Reside in rural setting 64.0 (16) 69.2 (63) .63
Completed high school 44.0 (11) 40.7 (37) .82
Gave birth previously 72.0 (18) 80.2 (73) .41
Number of live births (median [IQR]) 1 (0–1) 1 (1–2) .19
Married 8.0 (2) 4.4 (4) .61
Stable partner 92.0 (23) 92.3 (84) 1.00
Reported sexual intercourse per month (median [IQR]) 5 (4–6) 4 (3–7) .54
Number of sexual partners in lifetime (median [IQR]) 2 (2–3) 2 (1–3) .52
Reported always using a condom during sex 48.0 (12) 26.4 (24) .05
HSV-2 status during studya
Baseline positive 56.0 (14) 58.9 (53) .50
Acquired new infection 20.0 (5) 11.1 (10)
Remained negative 24.0 (6) 30.0 (27)
Genital discharge at sampled visit 24.0 (6) 13.3 (12) .23
Genital ulcer at sampled visit 0.0 (0) 2.2 (2) 1.00
Contraceptive choice at sampled visit
Injectable (Depo-Provera or Nur-Isterate) 80.0 (20) 82.4 (75) .73
Oral contraceptive pill 20.0 (5) 15.4 (14)
Tubal ligation/hysterectomy 0.0 (0) 2.2 (2)
Intravaginal insertions within 30 d of sampled visit 4.0 (1) 4.4 (4) 1.00
Intravaginal insertions at any point during trial 20.0 (5) 17.6 (16) .77
Sexually Transmitted Infections (by Polymerase
Chain Reaction)
Genital Inflammation
Present (n = 20)
Genital Inflammation
Absent (n = 68)
% (n) % (n)
Trichomonas vaginalis 40.0 (8) 20.6 (14) .09
Chlamydia trachomatis 20.0 (4) 16.2 (11) .74
Neisseria gonorrhoeae 5.0 (1) 4.4 (3) 1.00
HSV-2 5.0 (1) 2.9 (2) .54
Any one of the above sexually transmitted infections 50.0 (10) 33.8 (23) .20
Plasma Cytokine Concentration (pg/mL)b
Genital Inflammation
Present (n = 23)
Median (IQR)
Genital Inflammation
Absent (n = 84)
Median (IQR)
IL-1β 0.07 (0.01–0.23) 0.03 (0.01–0.14) .31
IL-1α 0.68 (0.68–0.68) 0.68 (0.68–0.68) .34
IL-6 0.86 (0.49–1.66) 0.78 (0.21–1.91) .47
IL-7 0.01 (0.01–0.08) 0.01 (0.01–0.33) .99
IL-8 1.73 (0.01–3.76) 1.87 (0.01–3.46) .88
IL-10 0.24 (0.24–8.12) 0.24 (0.24–6.02) .85
GM-CSF 0.89 (0.52–1.93) 0.86 (0.43–1.80) .55
TNF-α 3.72 (2.40–5.92) 3.63 (2.11–5.42) .77
IP-10 147.04 (99.85–246.13) 166.49 (111.27–253.28) .49
MCP-1 151.49 (122.68–218.63) 136.73 (86.62–198.16) .44
MIP-1β 15.63 (11.79–27.67) 24.75 (16.31–31.23) .19
MIP-1α 4.22 (0.21–8.40) 1.96 (0.21–5.52) .14
Sampled visit refers to the visit at which genital cytokine concentrations were assessed. Intravaginal insertions refer to reported insertion of any substance and/or
fingers into the genital tract.
Abbreviations: GM-CSF, granulocyte macrophage colony-stimulating factor; HSV-2, herpes simplex virus type-2; IL, interleukin; IP-10, interferon-γ inducible protein-
10; IQR, interquartile range; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; TNF-α, tumor necrosis factor-alpha.
a One woman had missing HSV-2 data.
b Plasma cytokine concentration data were available for a subset of 107 women (23 women who had genital inflammation and 84 women who did not have
inflammation).
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Since genital infections are associated with an increase in
local inflammatory cytokine concentrations [11, 12], we as-
sessed associations between inflammatory cytokines and com-
mon STIs. Half of the women with genital inflammation and
a third of women without genital inflammation had evidence
of an STI. Relatively few of the 116 women in this study had
vaginal discharge (n = 18) or genital ulceration (n = 2). Only 6
of 25 (24%) women who had an elevated genital inflammatory
profile had signs of an infection, and this did not differ signifi-
cantly in women who did not have inflammation (15%). Hence,
these genital conditions could not account for more than a
small fraction of the women with raised genital inflammatory
cytokine concentrations observed in this study.
Limitations of this study are that we were not able to screen
all of the women for STIs, due to samples not being available,
and we were not able to assess bacterial vaginosis as a potential
cause of genital inflammation. The role of bacterial vaginosis as
well as other possible causes of genital inflammation, including
vaginal hygiene practices [33], exposure to seminal proteins
[34], lubricants [35], hormone cycling [36], human papilloma
virus [37], and genital schistosomiasis [38], are being investigat-
ed in follow-on studies. All of the women in this study were
using placebo or tenofovir gel. Although there were no
differences in cytokine concentrations between these 2 groups,
both gels may have caused variation in cytokine levels at the in-
dividual level. It has been suggested that hydroxyethylcellulose
gel, which was used as the placebo in this trial, increases certain
genital cytokines [39] and may have altered genital inflamma-
tory profiles of the women who used gel in this study.
Several studies have suggested that demographic or geo-
graphic characteristics of women may influence the genital in-
flammatory environment [40, 41]. White women with normal
vaginal flora have been found to have higher cervical proin-
flammatory cytokine concentrations compared with black
women [40]. In addition, the allelic distribution at commonly
assayed sites in genes encoding certain proinflammatory cyto-
kines was found to differ significantly between white and black
populations [41]. Also, wide variation in genital cytokine con-
centrations has been observed in many studies within control
groups of women who do not have any common infections,
are not using hormone contraception, and do not have detect-
able seminal plasma in their genital secretions [11, 12, 36].
These findings suggest that the “normal” healthy immune mi-
lieu in the female genital tract differs at the population level
and at the individual level and may influence susceptibility
to HIV infection.
Figure 4. Cytokine concentrations in cervicovaginal lavage (CVL) samples from human immunodeficiency virus–uninfected placebo and tenofovir (TFV) gel
users. CVL cytokine concentrations in women who were using placebo gel (n = 70) are indicated by blue circles; red circles indicate those of TFV gel users
(n = 46). Lines indicate medians. No significant differences (P < .05) were found using Mann–Whitney U test. Abbreviations: GM-CSF, granulocyte macro-
phage colony-stimulating factor; IL, interleukin; IP-10, interferon-γ inducible protein-10; MCP, monocyte chemoattractant protein; MIP, macrophage inflam-
matory protein; TNF-α, tumor necrosis factor-alpha.
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Although the cytokines assessed in this study are well-
established biomarkers of cellular recruitment to the genital
tract and play important roles in genital inflammation [10, 24,
35], a limitation was that we did not have matching genital
tissue specimens available from women before they became
infected for assessment of HIV target-cell infiltration or more
in-depth mechanistic studies.
Younger women were found to have higher genital concentra-
tions of IL-6, IP-10, MCP-1, and MIP-1β compared with older
women, providing a possible reason, in addition to behavioral
factors, for the higher rates of HIV infection that are seen in
young South African women. Although women who later be-
came HIV-infected reported more frequent sexual activity than
those who did not become infected, the relationship between in-
flammation and risk of HIV infection was found to be indepen-
dent of the number and frequency of sex acts. Additionally,
genital cytokine concentrations were not associated with sexual
activity and did not differ between tenofovir and placebo gel
users. Women who did not have genital inflammation reported
less frequent condom use compared with women with an inflam-
matory profile, which may be due to differences in risk percep-
tion between the groups.
In conclusion, susceptibility to HIV infection was associated
with elevations in genital inflammatory cytokines, as a marker
of genital inflammation. The increased frequency of 4 inflamma-
tory cytokines in younger women may be an important driver of
the high HIV incidence rates in young women in Africa. While a
fraction of the genital inflammation may be attributed to asymp-
tomatic STIs, the dominant cause of genital inflammation re-
mains to be elucidated. Treatment of asymptomatic STIs and
topical agents to modulate inflammation are potentially impor-
tant mechanisms for reducing susceptibility to HIV infection,
especially in young women, where the epidemic is most severe
in Africa. These mechanisms require further investigation.
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